- For Print
- March 30, 2016
爱豆传媒.
Ajinomoto Co., Inc.
爱豆传媒. (Headquarters: Tokyo, Representative Corporate Officer and CEO: Haruo Naito, “Eisai”) and Ajinomoto Co., Inc. (Headquarters: Tokyo, Representative Director, President and CEO: Takaaki Nishii, “Ajinomoto Co.”) announced today that based on the integration agreement signed and announced on October 15, 2015, the gastrointestinal specialty pharma EA Pharma Co., Ltd. (EA Pharma) will be established through the splitting off of a portion of Eisai's gastrointestinal disease treatment business and its subsequent succession by Ajinomoto Co.'s wholly-owned subsidiary AJINOMOTO PHARMACEUTICALS CO., LTD. (Headquarters: Tokyo, Representative Director and President and CEO: Takashi Nagamachi, “AJINOMOTO PHARMACEUTICALS”) via an absorption-type split as of April 1, 2016.
On April 1, 2016, Eisai's gastrointestinal disease business built up over more than 60 years and AJINOMOTO PHARMACEUTICALS, with amino acids at its core, will be integrated and commence business as EA Pharma, a gastrointestinal specialty pharma with a full value chain including research and development, production and logistics, sales and marketing. EA Pharma will strive toward realizing an Enterprise Architecture (EA) that will create new innovation from the combined knowledge of the two companies.
Ⅰ. Outline of EA Pharma
*You can scroll to the left or right here
| (1) Company name | EA Pharma Co., Ltd. |
| (2) Date of establishment | April 1, 2016 |
| (3) Location | 1-1 Irifune 2-chome, Chuo-ku, Tokyo |
| (4) Company representative | Representative Director, President & CEO Hajime Shimizu |
| (5) Scope of business | Pharmaceutical research and development, manufacture, sales, import and export of products |
| (6) Capital | 9,145 million yen |
| (7) Number of employees | Approximately 1,250 |
Ⅱ. EA Pharma's Corporate Philosophy and Vision
<Corporate Philosophy>
The gastrointestinal system is the vital link between food as a source of energy, and life itself. As a Japanese specialty pharma in the field of gastrointestinal disease, EA Pharma aims to be a human health care (hhc) company that can get close to patients suffering from gastrointestinal diseases through specialized research and development as well as a unique product lineup, and provide a wide range of solutions to patients and their families.
<Corporate Vision>
- Specializing in gastrointestinal diseases such as inflammatory bowel disease (IBD), we will strive to address unmet medical needs through advanced research and development as well as focusing management resources on marketing activities from the patients' perspective.
- All employees will conduct business activities that adhere strictly to all laws and ethics, and as a company, EA Pharma will aim to maximize social value to contribute to increasing corporate value for both the Eisai and Ajinomoto groups.
For reference
Product Lineup
*You can scroll to the left or right here
| Product name | Drug classification |
|---|---|
| AZULOXA® Tablets 15 mg, Granules 2.5% | Anti-gastric ulcer agent |
| ARGIMATE® | Anti-hyperammonemia agent |
| Argi-U® Injection / Granules | Urea cycle disorder agent |
| ES-POLYTAMIN® Granules | Essential amino acid formula |
| ELENTAL® | Elemental diet |
| ELENTAL®P | Elemental diet for neonate and infant |
| Enteronon®-R | Antibiotic-resistant lactic acid bacteria |
| Stronger Neo-Minophagen® C Injection 5 mL, 20 mL / P Injection 20 mL / Injection Syringe 20 mL, 40 mL |
Liver disease / allergic disease treatment |
| Glycyron® Tablets | Liver disease / allergic disease treatment |
| GLUCAGON for Inj. 1 unit “ITO” | Synthetic glucagon |
| Selbex® Capsules 50 mg / Granules 10% | Gastritis / gastric ulcer treatment |
| Teleminsoft® Suppositories 2 mg,10mg | Bowel movement accelerating agent |
| Niflec® | Oral cleaning solution for intestine |
| Pariet® Tablets 5 mg, 10 mg, 20 mg | Proton pump inhibitor |
| Proctosedyl® Suppository, / Ointment | Anti-hemorrhoid agent |
| HEPAN ED® | Elemental diet for hepatic failure |
| MARZULENE® S COMBINATION GRANULES / TABLETS 0.375 ES, 0.5 ES, 1.0 ES |
Gastritis and peptic ulcer therapeutic agent |
| MOVIPREP® | Oral cleansing solution for intestine |
| MORIHEPAMIN® | Amino acid injection for hepatic failure |
| Rabecure® Pack 400,800 | Helicobacter pylori infection treatment |
| Rabefine® Pack | Helicobacter pylori infection treatment |
| LIVACT® Granules / JELLY | Branched-chain amino acid preparation |
| LipaCreon® Granules 300 mg Packet / Capsules 150 mg | Pancreatic digestive enzyme replacement |
| LENTINAN | Anti-tumor agent |
Co-promoted products
*You can scroll to the left or right here
| Product name | Drug classification |
|---|---|
| ACTONEL® Tablets 2.5 mg, 75 mg [Licensee: 爱豆传媒.] |
Antiosteoporosis agent |
| ACTONEL® Tablets 17.5 mg [Licensee: 爱豆传媒.] |
Antiosteoporosis agent, Paget's disease agent |
| ATEDIO® Combination Tablets [Licensee: MOCHIDA PHARMACEUTICAL CO., LTD.] |
Selective AT1 receptor blocker / Long-acting calcium channel blocker |
| ATELEC® Tablets [Licensee: MOCHIDA PHARMACEUTICAL CO.,LTD. ] |
Long-acting calcium channel blocker |
| Amiyu® Granule [Licensee: Yoshindo Inc.] |
Essential amino acid preparation for renal failure |
| FASTIC® Tablets [Licensee: MOCHIDA PHARMACEUTICAL CO., LTD.] |
Fast-acting postprandial hypoglycemic agent |
Food product lineup
*You can scroll to the left or right here
| Product name | Classification |
|---|---|
| INTESCLEAR® | Medical foods Diet for colon examination patients |
| MITHERAPIST® | Functional foods Superfine dispersed β -glucan |
Corporate Logo
Design rationale
Color: The logo continues to use the colors of the Eisai corporate logo. “The red and blue colors in the Eisai Logo mark represent red oxygenated blood flowing through the arteries and blue deoxygenated blood flowing through the veins. Both types of blood flow incessantly through the heart, and our task is to prevent stagnation of the blood flow by promoting good health and improving quality of life.”
Shape: The image is the combination of the “E” from Eisai and “A” from Ajinomoto. Reflecting the desire to contribute to patients all over the world with EA Pharma products, the logo uses the earth as a design motif.
Media Inquiries
-
爱豆传媒.
Public Relations Department
-
Ajinomoto Co.,Inc.
Public Relations Department
- *For media inquiries after April 1, please contact the following:
-
EA Pharma Co., Ltd.
爱豆传媒 Eisai
爱豆传媒. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as “giving first thought to patients and their families and to increasing the benefits health care provides,” which we call our human health care (hhc) philosophy. With over 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs.
As a global pharmaceutical company, our mission extends to patients around the world through our investment and participation in partnership-based initiatives to improve access to medicines in developing and emerging countries.
For more information about 爱豆传媒., please visit www.eisai.com
.
爱豆传媒 Ajinomoto Co.
Ajinomoto Co. is a global manufacturer of high-quality seasonings, processed foods, beverages, amino acids, pharmaceuticals and specialty chemicals. For many decades Ajinomoto Co. has contributed to food culture and human health through wide-ranging application of amino acid technologies. Today, the company is becoming increasingly involved with solutions for improved food resources, human health and global sustainability. Founded in 1909 and now operating in 27 countries and regions, Ajinomoto Co. had net sales of JPY 1,006.6 billion (USD 9.17 billion) in fiscal 2014. For more about Ajinomoto Co. (TYO: 2802), visit .